1. Home
  2. VRTX vs ADI Comparison

VRTX vs ADI Comparison

Compare VRTX & ADI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$457.11

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Logo Analog Devices Inc.

ADI

Analog Devices Inc.

HOLD

Current Price

$276.22

Market Cap

115.2B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRTX
ADI
Founded
1989
1965
Country
United States
United States
Employees
6100
N/A
Industry
EDP Services
Semiconductors
Sector
Technology
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
115.7B
115.2B
IPO Year
1991
1972

Fundamental Metrics

Financial Performance
Metric
VRTX
ADI
Price
$457.11
$276.22
Analyst Decision
Buy
Buy
Analyst Count
25
21
Target Price
$494.64
$282.00
AVG Volume (30 Days)
1.6M
4.7M
Earning Date
02-09-2026
11-25-2025
Dividend Yield
N/A
1.44%
EPS Growth
N/A
39.02
EPS
14.22
4.56
Revenue
$11,723,300,000.00
$11,019,707,000.00
Revenue This Year
$11.01
$17.89
Revenue Next Year
$8.74
$8.87
P/E Ratio
$32.08
$60.18
Revenue Growth
10.33
16.89
52 Week Low
$362.50
$158.65
52 Week High
$519.68
$284.23

Technical Indicators

Market Signals
Indicator
VRTX
ADI
Relative Strength Index (RSI) 61.34 60.98
Support Level $445.41 $270.14
Resistance Level $459.05 $284.23
Average True Range (ATR) 10.50 5.34
MACD 0.26 -1.26
Stochastic Oscillator 83.14 39.33

Price Performance

Historical Comparison
VRTX
ADI

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About ADI Analog Devices Inc.

Analog Devices is a leading analog, mixed-signal, and digital-signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers; more than half of its chip sales are to industrial and automotive end markets. ADI's chips are also incorporated into wireless infrastructure equipment.

Share on Social Networks: